Vitamin D May Not Provide Protection from COVID-19 Susceptibility, Disease Severity


Study shows no evidence for an association between genetically predicted vitamin D levels and COVID-19 susceptibility, hospitalization, or severe disease

Although observational studies indicate that greater levels of vitamin D may protect against COVID-19, these studies are inconclusive and potentially subject to confounding, according to an analysis published in PLOS Medicine. The study suggests that genetic evidence does not support vitamin D as a protective measure against COVID-19.1

Increased vitamin D levels, as reflected by 25-hydroxy vitamin D (25OHD) measurements, have been hypothesized to offer protection against COVID-19 based on in vitro, observational, and ecological studies. Although vitamin D levels are associated with multiple confounding variables, these associations may not be causal, according to the authors of the current study.2

To further assess the relationship between vitamin D levels and COVID-19 susceptibility and severity, the research team conducted a Mendelian randomization study using genetic variants strongly associated with increased vitamin D levels. The study authors examined genetic variants from 4134 individuals with COVID-19, and 1,284,876 people without COVID-19, across 11 countries to determine whether genetic predisposition for higher vitamin D levels were associated with less severe disease outcomes in COVID-19.1

The findings showed no evidence for an association between genetically predicted vitamin D levels and COVID-19 susceptibility, hospitalization, or severe disease. The researchers said this suggests that raising circulating vitamin D levels via supplementation may not improve COVID-19 outcomes in the general population.1

The study had some key limitations, including that it did not include individuals with vitamin D deficiency, with the authors noting that it is possible that deficient patients may benefit from supplementation for COVID-19-related protection and outcomes. Further, the genetic variants were used only from individuals of European ancestry, therefore future research is necessary to evaluate the relationship with COVID-19 outcomes in other populations.1

"Vitamin D supplementation as a public health measure to improve outcomes is not supported by this study,” the study authors said in a press release. “Most importantly, our results suggest that investment in other therapeutic or preventative avenues should be prioritized for COVID-19 randomized clinical trials.”1

The study authors concluded that other therapeutic avenues should be given higher priority for COVID-19 randomized controlled trials.2


  1. Vitamin D may not provide protection from COVID-19 susceptibility or disease severity. EurekAlert! Published June 1, 2021. Accessed June 3, 2021.
  2. Laporte-Butler G, Nakanishi T, Mooser V, et al. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. PLOS. Published June 1, 2021.
Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim -
Patient suffering from atopic dermatitis -- Image credit: Nikkikii |
Image credit: Fabio Balbi |
Image credit: Melita -
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская |
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS |
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz -
Image credit: New Africa |
© 2024 MJH Life Sciences

All rights reserved.